Abstract PS1-03: Active surveillance for DCIS: Clinical outcomes at 5.6 years mean follow-up
Case Brabham(Harvard University), Laura J. Esserman(University of California, San Francisco), Heather Greenwood(University of California, San Francisco), Amrita Basu(University of Calcutta), Alexander D. Borowsky(University of California, San Francisco), Gillian L. Hirst(University of California, San Francisco), Rita L. Freimanis(University of California, San Francisco), Paul Kim(Quinnipiac University), Gregor Krings(Cleveland Clinic), Shelley Hwang(Duke University), Rick Baehner(University of California, San Francisco), Nola Hylton(University of California, San Francisco), Rita Mukhtar(University of California, San Francisco), April S. Liang(University of California, San Francisco)
Cited by 0
Related Papers
Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer
|JAMA Oncology|2020|707
Comprehensive analysis of normal adjacent to tumor transcriptomes
|Nature Communications|2017|663
Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer
|Nature Medicine|2016|539